Oryzon Genomics (MEX:ORYN) Total Equity: MXN2,452.65 Mil (As of Mar. 2026)


MEX:ORYN Oryzon Genomics SA MEX:ORYN
31 GF Score
Price MXN48.59
View Full Analysis

What is Oryzon Genomics Total Equity?

Oryzon Genomics MEX:ORYN 31 Total Equity is MXN2,452.65 Mil as of Mar. 2026. GuruFocus rates MEX:ORYN with a GF Score™ of 31/100.

Oryzon Genomics's total equity for the quarter that ended in Mar. 2026 was MXN2,452.65 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Oryzon Genomics Total Equity Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Total Equity Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,655.15 1,517.30 1,534.37 1,913.49 2,492.49

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,889.01 2,522.02 2,512.68 2,492.49 2,452.65
MEX:ORYN
31GF Score
Oryzon Genomics SA MEX:ORYN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Oryzon Genomics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3056.666-564.173
=2,492.49

Oryzon Genomics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2938.068-485.422
=2,452.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of MXN2,452.65 Mil mean?
Oryzon Genomics (MEX:ORYN) has a Total Equity of MXN2,452.65 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Oryzon Genomics and its competitors.
Is Oryzon Genomics' Total Equity too high?
Oryzon Genomics' current Total Equity is MXN2,452.65 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Total Equity compare to VRTX and REGN?
Oryzon Genomics' Total Equity of MXN2,452.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Oryzon Genomics and its competitors. Oryzon Genomics's current Total Equity is MXN2,452.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current Total Equity of MXN2,452.65 Mil. The current Total Equity is MXN2,452.65 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current Total Equity is MXN2,452.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for MEX:ORYN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.59
Price